NSABP B-47 was a phase 3 trial in which 3270 women with high-risk, HER2-low breast cancer were randomized to chemotherapy with or without trastuzumab between 2011 and 2015 [10]. This evidence concerns the gene ERBB2 and breast carcinoma.